not sure if you fellas know but I posted friday saying volume was higher. I didn't know why till this weekend. DB upgraded or reiterated it's "BUY" rating and said 56 target. Gave more details but this is the gist. If anyone wants more details (about 2-3 sentences), I'll post if asked and when I get time. THX
If one looks to the last financial report there are triggers coming too.
"-Third quarter 2012 total revenues of $336 million, including third quarter 2012 net product revenues of approximately $254 million for INCIVEK in hepatitis C and $49 million for KALYDECO in cystic fibrosis-
-Cystic Fibrosis: Three ongoing Phase 3 label expansion studies for ivacaftor monotherapy; pivotal program for VX-809 and ivacaftor combination expected to begin in early 2013-
-Hepatitis C: Planned start of first all-oral Phase 2 study of VX-135 by the end of 2012; agreements with GlaxoSmithKline and Janssen Pharmaceuticals announced today provide opportunity to study VX-135 in additional all-oral regimens in Phase 2 studies-"
As to triggers, Kalydeco was recently approved in Canada so more countries should be coming online soon too and sales will increase.
okay, sounds weak to me. we went up almost $2 from the low. wonder if there is news or some fund just said this is worth $60 or more and they just kept buying. Not like 1.7MM shares is a lot of money for a fund.